Review Challenge: Deduce Efficacy From One Subset Of One Single-Arm Trial
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Genmab and GlaxoSmithKline provided FDA with data from two trials to support the efficacy of Arzerra in refractory chronic lymphocytic leukemia, but the agency only considered a subset of one of the studies to count for proof of efficacy
You may also be interested in...
Context Is Key To Accelerated Approval In Oncology, Arzerra Review Shows
By targeting a population with an unmet medical need that would qualify for review under FDA's accelerated approval regulations, GlaxoSmithKline and Genmab transcended a "suboptimal" development program and "uncertainty" regarding the magnitude of treatment effect to bring their anti-CD20 monoclonal antibody Arzerra (ofatumumab) to market, FDA review documents show